OBJECTIVES The purpose of this study was to determine the risk factors for ischemic in hemorrhage cerebrovascular events in patients supported by the HeartWare ventricular assist device (HVAD).
L eft ventricular assist devices (LVADs) are used with increasing frequency in patients with advanced systolic heart failure both as a bridge to transplant (BTT) and as destination therapy (1-3).
The current generation of continuous flow devices provides excellent survival and quality of life, affords greater durability, and allows for less extensive surgical dissection and implantation in a wider variety of patients than the pulsatile technology these devices supplanted. However, despite these advances, patients remain at risk for serious adverse events such as infection, bleeding, thrombus, and stroke (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) .
Cerebrovascular accidents (CVAs) can be especially devastating, and, if not fatal, they often lead to permanent disability, dramatically reducing quality of life and negatively affecting transplant candidacy.
The reported prevalence of CVA after implantation of continuous flow LVADs ranges from 7% to 15% (15) (16) (17) (18) (19) . CVAs, particularly hemorrhagic cerebrovascular accidents (HCVAs), often account for a significant proportion of deaths for patients on ventricular assist device (VAD) support. Other studies have implicated sepsis and excessive anticoagulation as risk factors for hemorrhagic stroke, but no comprehensive multivariable analysis of risk factors for stroke in patients with continuous flow VADs has been published (6, 20, 21) . Given the morbidity and mortality of CVAs complicating VAD therapy, we examined the prevalence and rates of neurological events from the HeartWare BTT trial and continued access protocol (CAP). Our goal was to determine the impact that changes to device design had on CVAs and to identify modifiable risk factors.
METHODS
The design of the HeartWare HVAD BTT and CAP clinical trial has been described previously (22) . 
RESULTS
A total of 382 patients were included in the study. As shown in Figure 1 , the overall prevalence of ICVA was 6.8% (26 of 382); for HCVA, it was 8.4% (32 of 382).
Seven patients experienced periprocedural (within Figure 4A , multivariable predictors of ICVA were aspirin #81 mg (HR: 7.1) and atrial fibrillation (HR: 2.9). As shown in 0.08 EPPY; p ¼ NS) ( Table 3 ). Both HCVAs (3.0% at 0.04 EPPY) and ICVAs (0% at 0.00 EPPY) were infrequent in 33 patients at IBPM sites after the design modifications.
Although there was no difference in the baseline incidence of hypertension in patients with and without stroke, given the data observed in the Heart Failure Study reported that in patients with heart failure, there was a statistically significant 4-fold excess in strokes compared with subjects without cardiac disease (28) . In patients with atrial fibrillation, the risk of stroke increased with age, ranging from 1.5% in the 50-to 59-year-old age group to 9.9% in the 70-to 79-year-old age group. However, the greatest attributable risk of stroke, independent of age, occurred in patients with hypertension, with an attributable risk of approximately 50% (25) . Interestingly, we found no association between pre-implantation patient characteristics and stroke risk, suggesting that the patient-VAD interface as well as post-implantation comorbidities and management are drivers of this adverse event rather than patient selection. The multivariable analysis further showed that aspirin 
CONCLUSIONS
The use of HVAD as a BTT was associated with excellent outcomes and long-term survival. However, stroke after HVAD implantation remains a significant cause of morbidity and mortality and limits the overall effectiveness of the therapy. Nearly 10% of patients will experience either an ischemic or ICVA patients having a procedural event (#48 h of implantation, n ¼ 7) and HCVAs that were either iatrogenic (n ¼ 3) or the result of a fall (n ¼ 2 patients with 3 events) were excluded. *Indicates statistically significant difference between non-improved blood pressure management (IBPM) and IBPM, p ¼ 0.008. †Indicates a trend from non-IBPM to IBPM, p ¼ 0.056.
EPPY ¼ events per patient-year; HVAD ¼ HeartWare ventricular assist device; PY ¼ patient-year; other abbreviations as in Table 1 . clinical study with pre-specified care incorporating these management practices.
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